Literature DB >> 8587459

Human pericardial fluid contains the highest amount of endothelin-1 of all mammalian biologic fluids thus far tested.

F Horkay1, M Laine, I Szokodi, J Leppäluoto, O Vuolteenaho, H Ruskoaho, A Juhász-Nagy, M Tóth.   

Abstract

Immunoreactive endothelin-1 (ET-1) levels were measured in the pericardial fluid (PF), plasma (PL), and atrial and ventricular tissues of 16 cardiac surgical patients. ET-1 was higher in the PF (73 +/- 11 pg/ml) than in the PL/3.33 +/- 0.51 pg/ml; p < 0.05/. PF/PL ratio ranged from 8 to as high as 200. An inverse relationship was found between the NYHA stage and ET-1 concentrations in PF, whereas ET-1 in PL did not have any relation to the NYHA stage of the disease. In HPLC analysis, the total immunoreactive ET-1 in PF from five different patients co-eluted with the human ET-1 standard. The results indicate that ET-1 concentrations in human PF can be several-fold those in the PL. The source and function of the ET-1 in PF requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587459

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Increased pericardial fluid concentrations of the mature form of adrenomedullin in patients with cardiac remodelling.

Authors:  K Tambara; M Fujita; N Nagaya; S Miyamoto; A Iwakura; K Doi; G Sakaguchi; K Nishimura; K Kangawa; M Komeda
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

2.  Modulation by endothelin-1 of spontaneous activity and membrane currents of atrioventricular node myocytes from the rabbit heart.

Authors:  Stéphanie C Choisy; Hongwei Cheng; Godfrey L Smith; Andrew F James; Jules C Hancox
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

3.  Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy.

Authors:  Zoltan Nemeth; Attila Cziraki; Sandor Szabados; Bernadett Biri; Sandor Keki; Akos Koller
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.